Molecular mechanisms of α-synuclein neurodegeneration

被引:164
作者
Waxman, Elisa A. [1 ]
Giasson, Benoit I. [1 ]
机构
[1] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2009年 / 1792卷 / 07期
关键词
alpha-synuclein; Amyloid; Fibril; Parkinson's disease; Protofibril; Toxicity; MULTIPLE SYSTEM ATROPHY; SOLUBLE AMYLOID OLIGOMERS; BRAIN IRON ACCUMULATION; CHAPERONE-LIKE ACTIVITY; DOPAMINE NEURON DEATH; PARKINSONS-DISEASE; LEWY BODIES; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; TRANSGENIC MICE;
D O I
10.1016/j.bbadis.2008.09.013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
alpha-Synuclein is an abundant highly charged protein that is normally predominantly localized around synaptic vesicles in presynaptic terminals. Although the function of this protein is still ill-defined, genetic studies have demonstrated that point mutations or genetic alteration (duplications or triplications) that increase the number of copies of the alpha-synuclein (SCNA) gene can cause Parkinson's disease or the related disorder dementia with Lewy bodies. alpha-Synuclein can aberrantly polymerize into fibrils with typical amyloid properties, and these fibrils are the major component of many types of pathological inclusions, including Lewy bodies, which are associated with neurodegenerative diseases, such as Parkinson's disease. Although there is substantial evidence supporting the toxic nature of alpha-synuclein inclusions, other modes of toxicity such as oligomers have been proposed. In this review, some of the evidence for the different mechanisms of alpha-synuclein toxicity is presented and discussed. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:616 / 624
页数:9
相关论文
共 169 条
[1]   Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system [J].
Abeliovich, A ;
Schmitz, Y ;
Fariñas, I ;
Choi-Lundberg, D ;
Ho, WH ;
Castillo, PE ;
Shinsky, N ;
Verdugo, JMG ;
Armanini, M ;
Ryan, A ;
Hynes, M ;
Phillips, H ;
Sulzer, D ;
Rosenthal, A .
NEURON, 2000, 25 (01) :239-252
[2]   A-synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells [J].
Ahn, BH ;
Rhim, H ;
Kim, SY ;
Sung, YM ;
Lee, MY ;
Choi, JY ;
Wolozin, B ;
Chang, JS ;
Lee, YH ;
Kwon, TK ;
Chung, KC ;
Yoon, SH ;
Hahn, SJ ;
Kim, MS ;
Jo, YH ;
Min, DS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (14) :12334-12342
[3]   Pure autonomic failure in association with human α-synucleinopathy [J].
Arai, K ;
Kato, N ;
Kashiwado, K ;
Hattori, T .
NEUROSCIENCE LETTERS, 2000, 296 (2-3) :171-173
[4]   Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein [J].
Arawaka, S ;
Saito, Y ;
Murayama, S ;
Mori, H .
NEUROLOGY, 1998, 51 (03) :887-889
[5]   Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding α-synuclein [J].
Athanassiadou, A ;
Voutsinas, G ;
Psiouri, L ;
Leroy, E ;
Polymeropoulos, MH ;
Ilias, A ;
Maniatis, GM ;
Papapetropoulos, T .
AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (02) :555-558
[6]   Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease [J].
Auluck, PK ;
Chan, HYE ;
Trojanowski, JQ ;
Lee, VMY ;
Bonini, NM .
SCIENCE, 2002, 295 (5556) :865-868
[7]  
Baba M, 1998, AM J PATHOL, V152, P879
[8]   Parkinson's disease-associated α-sylnuclein is more fibrillogenic than β- and γ-synuclein and cannot cross-seed its homologs [J].
Biere, AL ;
Wood, SJ ;
Wypych, J ;
Steavenson, S ;
Jiang, YJ ;
Anafi, D ;
Jacobsen, FW ;
Jarosinski, MA ;
Wu, GM ;
Louis, JC ;
Martin, F ;
Narhi, LO ;
Citron, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (44) :34574-34579
[9]   Residual structure and dynamics in Parkinson's disease-associated mutants of α-synuclein [J].
Bussell, R ;
Eliezer, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (49) :45996-46003
[10]  
Cabin DE, 2002, J NEUROSCI, V22, P8797